1. Home
  2. RDHL vs HAO Comparison

RDHL vs HAO Comparison

Compare RDHL & HAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • HAO
  • Stock Information
  • Founded
  • RDHL 2009
  • HAO 2018
  • Country
  • RDHL Israel
  • HAO China
  • Employees
  • RDHL N/A
  • HAO 30
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • HAO
  • Sector
  • RDHL Health Care
  • HAO
  • Exchange
  • RDHL Nasdaq
  • HAO NYSE
  • Market Cap
  • RDHL 6.8M
  • HAO 6.6M
  • IPO Year
  • RDHL N/A
  • HAO 2024
  • Fundamental
  • Price
  • RDHL $5.23
  • HAO $2.00
  • Analyst Decision
  • RDHL
  • HAO
  • Analyst Count
  • RDHL 0
  • HAO 0
  • Target Price
  • RDHL N/A
  • HAO N/A
  • AVG Volume (30 Days)
  • RDHL 10.4K
  • HAO 7.0M
  • Earning Date
  • RDHL 04-07-2025
  • HAO 10-29-2024
  • Dividend Yield
  • RDHL N/A
  • HAO N/A
  • EPS Growth
  • RDHL N/A
  • HAO 20.20
  • EPS
  • RDHL N/A
  • HAO 0.04
  • Revenue
  • RDHL $3,707,000.00
  • HAO $48,519,836.00
  • Revenue This Year
  • RDHL $224.90
  • HAO N/A
  • Revenue Next Year
  • RDHL $82.69
  • HAO N/A
  • P/E Ratio
  • RDHL N/A
  • HAO $2.47
  • Revenue Growth
  • RDHL N/A
  • HAO 71.88
  • 52 Week Low
  • RDHL $5.20
  • HAO $0.09
  • 52 Week High
  • RDHL $20.28
  • HAO $10.60
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 31.92
  • HAO 61.24
  • Support Level
  • RDHL $5.52
  • HAO $1.75
  • Resistance Level
  • RDHL $5.71
  • HAO $2.02
  • Average True Range (ATR)
  • RDHL 0.27
  • HAO 0.35
  • MACD
  • RDHL -0.04
  • HAO -0.06
  • Stochastic Oscillator
  • RDHL 2.38
  • HAO 11.03

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About HAO HAOXI HEALTH TECHNOLOGY LTD

Haoxi Health Technology Ltd is an online marketing solution provider in China, with an advertiser client base mainly in the healthcare industry. Haoxi has been rooted in the field of local online effect marketing for many years, serving customers in various industries at home and abroad, and its main business is the medical industry. It generates its revenue by providing one-stop online marketing solutions, in particular online short video marketing solutions, to advertisers through its media partners. The company provides customized marketing solutions by planning, producing, placing, and optimizing online ads, especially online short video ads, to help its advertisers acquire, convert, and retain ultimate consumers on various online media platforms.

Share on Social Networks: